Please assess the completion status of the following clinical trial:

Trial Title: Effect of the Vitreous in Response to Intravitreal Injections of Ranibizumab for the Treatment of Diabetic Macular Edema

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* at least 18 years of age with either type 1 or type 2 diabetes mellitus;~* maximal central subfield foveal thickness (CSF) of at least 300μm (according to SD-OCT images - Spectral Domain Optical Coherence Tomography);~* BCVA of 20 to 80 letters, using ETDRS letters chart;~* ability to provide written informed consent.~Exclusion Criteria:~* Pregnant or lactating;~* Epiretinal membrane (ERM) existence in the study eye;~* persistent posterior hyaloid adherence after vitrectomy for group 2;~* previous vitrectomy for group 1;~* history of other retinal vascular diseases in the study eye;~* LASER photocoagulation or intravitreal injections (IV) of anti-VEGF or systemic anti-VEGF or pro-anti-VEGF treatment and cataract surgery in the 6 months previously to the study eye inclusion;~* IV or peribulbar corticosteroid injections in the 6 months previously to study eye inclusion;~* history of IV of implant of fluocinolone acetonide in the study eye;~* vitreous hemorrhage or opacification in the study eye;~* active proliferative diabetic retinopathy in the study eye;~* active ocular inflammation or infection in either eye;~* aphakia in the study eye;~* other causes for macular edema, for example, after cataract surgery in the study eye;~* other causes of visual loss in the study eye;~* other diseases that may affect the course of macular edema in the study eye;~* uncontrolled glaucoma in either eye (intraocular pressure \> 24 mmHg with treatment);~* history of arterial thrombotic event in the previous 6 months;~* uncontrolled arterial hypertension (systolic blood pressure \>160 mmHg or diastolic blood pressure \> 100 mmHg);~* ward of the state.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- non vitrectomized eyes (Type: None): ranibizumab injections (0.5 mg/0.05ml) following a PRN regimen
- vitrectomized eyes (Type: None): ranibizumab injections (0.5 mg/0.05ml) following a PRN regimen

Based on this trial design, predict the completion outcome and termination type (if applicable).